Q1 2023 Results

Company overview Financial review Conclusions Appendix References Expected currency impact for full year 2023 Currency impact vs. PY %pts, assuming late-April exchange rates prevail in 2023 FX impact on Net sales -6 FY I 2022 I FX impact on Core operating income 0 + -1 I I -5 Q1 Q2 FY Actual Simulation 28 Investor Relations | Q1 2023 Results 2023 -8 FY I 2022 I I FINANCIAL PROFILE -3 to -4 -5 -7 Q1 Q2 FY 2023 NOVARTIS | Reimagining Medicine

View entire presentation